Tumor-Infiltrating Clonal Hematopoiesis | NEJM
Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition associated with increased mortality among patients with cancer. CHIP mutations with high variant-allele frequencie…
Related Articles
Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer | NEJM
Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC). Zongertinib is an oral, irreversible,…
Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer | NEJM
Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC). Zongertinib is an oral, irreversible,…
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation | NEJM
Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as…
Routine Surveillance for Cancer Metastases — Does It Help or Harm Patients? | NEJM
Research generally suggests that routine surveillance after cancer treatment finds more recurrences — leading to more surgery, chemotherapy, and radiation — without affecting the risk…
Eustrongylidiasis — A Parasitic Infection Acquired by Eating Sushi | NEJM
IN recent years raw fish has come to be seen as a delicacy in the United States. It is now served in numerous restaurants across…
Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer | NEJM
Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC). Zongertinib is an oral, irreversible,…
Nonoperative Management of Mismatch Repair–Deficient Tumors | NEJM
Among patients with mismatch repair–deficient (dMMR), locally advanced rectal cancer, neoadjuvant checkpoint blockade eliminated the need for surgery in a high proportion of patients. Whether…
Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer | NEJM
Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC). Zongertinib is an oral, irreversible,…
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis | NEJM
In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP…